SPECTRUM PHARMACEUTICALS INC Form 8-K October 18, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 14, 2016
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-35006 93-0979187
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
11500 S. Eastern Ave., Ste. 240, Henderson, NV 89052
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (702) 835-6300
Not Applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
" Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
" Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form 8-K

Item 8.01 Other Events.

On October 14, 2016, Luigi Lenaz, MD was appointed as Lead Director of Spectrum Pharmaceuticals, Inc. A press release dated October 18, 2016 announcing this appointment is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description99.1 Press Release dated October 18, 2016

Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Spectrum Pharmaceuticals, Inc.

Date: October 18, 2016 By: /s/ Kurt A. Gustafson Kurt A. Gustafson Executive Vice President and Chief Financial Officer EXHIBIT INDEXExhibit No.Description99.1Press Release dated October 18, 2016.